JP2009515824A - 生体外の／コンピュータによる予測を用いた酸化窒素供与体（ジアゼン―１―イウム―１、２―ジオラート部分）を有するプロドラッグの開発 - Google Patents

生体外の／コンピュータによる予測を用いた酸化窒素供与体（ジアゼン―１―イウム―１、２―ジオラート部分）を有するプロドラッグの開発 Download PDF

Info

Publication number
JP2009515824A
JP2009515824A JP2008535771A JP2008535771A JP2009515824A JP 2009515824 A JP2009515824 A JP 2009515824A JP 2008535771 A JP2008535771 A JP 2008535771A JP 2008535771 A JP2008535771 A JP 2008535771A JP 2009515824 A JP2009515824 A JP 2009515824A
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
formula
structural formula
nitric oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008535771A
Other languages
English (en)
Japanese (ja)
Inventor
ユン カウ タム
クリストファー マーク ダイパー
ヒュー エー． センプル
ダグラス サーチャー リッジウェイ
イーチャン ジェームス リン
ブライアン ダフ スローリー
Original Assignee
ノボキン バイオテック インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノボキン バイオテック インク． filed Critical ノボキン バイオテック インク．
Publication of JP2009515824A publication Critical patent/JP2009515824A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2008535771A 2005-10-13 2006-10-13 生体外の／コンピュータによる予測を用いた酸化窒素供与体（ジアゼン―１―イウム―１、２―ジオラート部分）を有するプロドラッグの開発 Pending JP2009515824A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72653005P 2005-10-13 2005-10-13
US73012005P 2005-10-21 2005-10-21
US75644606P 2006-01-05 2006-01-05
US81223006P 2006-06-09 2006-06-09
PCT/US2006/040382 WO2007044963A2 (fr) 2005-10-13 2006-10-13 Développement de promédicaments possédant une entité 1,2-diolate de diazén-1-ium donneuse d'oxyde nitrique en utilisant des prédictions in vitro/in silico

Publications (1)

Publication Number Publication Date
JP2009515824A true JP2009515824A (ja) 2009-04-16

Family

ID=37943584

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008535771A Pending JP2009515824A (ja) 2005-10-13 2006-10-13 生体外の／コンピュータによる予測を用いた酸化窒素供与体（ジアゼン―１―イウム―１、２―ジオラート部分）を有するプロドラッグの開発

Country Status (5)

Country Link
EP (1) EP1934872A2 (fr)
JP (1) JP2009515824A (fr)
AU (1) AU2006299818A1 (fr)
CA (1) CA2622150A1 (fr)
WO (1) WO2007044963A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531018A (ja) * 2014-10-15 2017-10-19 ノバルティス アーゲー 緑内障および高眼圧症を治療するためのプロスタグランジン複合体および誘導体

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102043892B (zh) * 2009-10-23 2014-04-02 上海开拓者医药发展有限公司 用于原料药胃肠道吸收预测的bspk模型的建模和使用方法
US8633177B2 (en) 2010-03-19 2014-01-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxyl (HNO) releasing compounds and uses thereof in treating diseases
CN115512788B (zh) * 2022-09-16 2023-08-08 山东大学 预测SGLTi人体暴露量及靶蛋白抑制率的方法及系统

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531018A (ja) * 2014-10-15 2017-10-19 ノバルティス アーゲー 緑内障および高眼圧症を治療するためのプロスタグランジン複合体および誘導体
JP2020023556A (ja) * 2014-10-15 2020-02-13 ノバルティス アーゲー 緑内障および高眼圧症を治療するためのプロスタグランジン複合体および誘導体

Also Published As

Publication number Publication date
CA2622150A1 (fr) 2007-04-19
WO2007044963A3 (fr) 2009-04-30
WO2007044963A2 (fr) 2007-04-19
WO2007044963A8 (fr) 2007-06-14
AU2006299818A1 (en) 2007-04-19
EP1934872A2 (fr) 2008-06-25

Similar Documents

Publication Publication Date Title
US20080288176A1 (en) Development of Prodrugs Possessing a Nitric Oxide Donor Diazen-1-Ium-1,2-Diolate Noiety Using in Vitro/in Silico Predictions
Ferrario Angiotensin-converting enzyme 2 and angiotensin-(1-7) an evolving story in cardiovascular regulation
Li et al. The complex effects of the slow‐releasing hydrogen sulfide donor GYY 4137 in a model of acute joint inflammation and in human cartilage cells
Marathe et al. The use of radiolabeled compounds for ADME studies in discovery and exploratory development
Steiger et al. Prevention of colitis by controlled oral drug delivery of carbon monoxide
Tuma et al. Elucidation of reaction scheme describing malondialdehyde− acetaldehyde− protein adduct formation
Wells et al. Interactions between oxaprozin glucuronide and human serum albumin
JPS62267222A (ja) 不飽和脂肪酸含有製剤
Kaur et al. Synthesis and biological investigations of nitric oxide releasing nateglinide and meglitinide type II antidiabetic prodrugs: In-vivo antihyperglycemic activities and blood pressure lowering studies
Machulkin et al. Synthesis and biological evaluation of PSMA ligands with aromatic residues and fluorescent conjugates based on them
JP2009515824A (ja) 生体外の／コンピュータによる予測を用いた酸化窒素供与体（ジアゼン―１―イウム―１、２―ジオラート部分）を有するプロドラッグの開発
Shen Toward more selective antiarthritic therapy
Galligan et al. Histone adduction and its functional impact on epigenetics
Sang et al. An “AND” Molecular Logic Gate as a Super‐Enhancers for De Novo Designing Activatable Probe and Its Application in Atherosclerosis Imaging
Gilbert et al. Subcellular delivery of hydrogen sulfide using small molecule donors impacts organelle stress
Kamo et al. Impact of FDA-approved drugs on the prostaglandin transporter OATP2A1/SLCO2A1
Nakayama Wong et al. Differential cellular responses to protein adducts of naphthoquinone and monocrotaline pyrrole
Reddi et al. Sulfamate acetamides as self-immolative electrophiles for covalent ligand-directed release chemistry
Talmon et al. Design, synthesis and biological evaluation of vortioxetine derivatives as new COX-1/2 inhibitors in human monocytes
Shi et al. Real-time visualization of the antioxidative potency of drugs for the prevention of myocardium ischemia-reperfusion injury by a NIR fluorescent nanoprobe
Russo et al. Ketogal: a derivative ketorolac molecule with minor ulcerogenic and renal toxicity
Ren et al. Mechanistic evaluation of anti-arthritic activity of β-methylphenylalanine in experimental rats
US20100310540A1 (en) Methods of screening for compounds that modulate tafia activity, compounds, and methods of using the compounds
Kantharaj et al. Histone deacetylase inhibitors as therapeutic agents for cancer therapy: Drug metabolism and pharmacokinetic properties
Bassanini et al. Perfluorinated probes for noncovalent protein recognition and isolation